Treatment Selection and Timing Considerations in IDH-Mutant Glioma

Dr. Sener raises practical questions about optimal treatment timing given the broad FDA approval spanning gross total resection to biopsy-only patients. The approval allows treatment initiation immediately post-surgery or at later timepoints based on clinical judgment.

Dr. Cloughesy differentiates his approach between oligodendrogliomas and astrocytomas. For oligodendrogliomas with clear gross total resections, he's comfortable with monitoring given their slower growth patterns, though careful scan review at 3 months post-surgery helps distinguish true gross total resection from minimal residual disease.

For astrocytomas, he advocates earlier treatment initiation due to the disease's inherently aggressive nature. Even grade 2 astrocytomas demonstrate concerning behavior, making him uncomfortable with prolonged observation periods. His practice involves starting vorasidenib earlier in astrocytoma patients regardless of resection extent.

Both panelists acknowledge that microscopic invisible disease persists even after apparent gross total resection, providing rationale for early treatment to delay subsequent progression and avoid radiation or chemotherapy.

For higher-grade tumor settings, patients frequently inquire about vorasidenib use as maintenance therapy following radiation and chemotherapy. Dr. Cloughesy prefers waiting for clinical trial results studying combination with radiation/chemotherapy or maintenance strategies rather than encouraging off-label use.

However, he acknowledges that if patients insist on treatment despite counseling against off-label use, he'll provide close monitoring rather than lose them to other providers. The excellent tolerability profile creates arguments for potential benefit, though definitive evidence remains lacking.